Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 53Carcinoma, Hepatocellular 43Breast Neoplasms 33Small Cell Lung Carcinoma 29Squamous Cell Carcinoma of Head and Neck 23Cholangiocarcinoma 22Urinary Bladder Neoplasms 21Colorectal Neoplasms 21Pancreatic Neoplasms 20Ovarian Neoplasms 17Triple Negative Breast Neoplasms 16Biliary Tract Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 12Neoplasms 11Carcinoma, Renal Cell 11Liver Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Uterine Cervical Neoplasms 7Esophageal Neoplasms 7Carcinoma, Squamous Cell 7Adenocarcinoma Of Esophagus 7Recurrence 6Prostatic Neoplasms 6Mesothelioma, Malignant 6Melanoma 6Gallbladder Neoplasms 6Fallopian Tube Neoplasms 6

Interventions

pembrolizumab 7Paclitaxel 4Cisplatin 3Carboplatin 3camrelizumab 2Radiotherapy 2Radiosurgery 2Nivolumab 2Immunotherapy 2Immune Checkpoint Inhibitors 2tremelimumab 1toripalimab 1spartalizumab 1sinoporphyrin sodium 1poly ICLC 1penpulimab 1durvalumab 1avelumab 1Tramadol 1Tadalafil 1Surgical Procedures, Operative 1S 1 (combination) 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Photochemotherapy 1Pemetrexed 1Oxaliplatin 1Morphine 1Leucovorin 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Parkinson Disease 4, Autosomal Dominant Lewy Body × durvalumab × Clear all
NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Ludwig Institute for Cancer Research

Phase 1/2 Completed
73 enrolled 18 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡